GlassScriptPhysician profile
George Stephen Lawrence
NPI 1245237528
$1,914.60
in general payments reported to CMS, 2019-2025
22 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $179 · 2021: $161 · 2022: $195 · 2023: $470 · 2024: $292 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.78 |
| Education | $134.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $444.72 | 2019-2024 | Evenity |
| Abbvie INC. | $232.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $228.03 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $181.00 | 2023-2025 | |
| Astellas Pharma US INC | $159.16 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $148.61 | 2022-2025 | |
| Abbott Laboratories | $129.12 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Merck Sharp & Dohme LLC | $60.94 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $55.54 | 2022-2024 | Spravato |
| Nestle Healthcare Nutrition INC. | $45.58 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.76 | 2023-2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $25.21 | 2023 | |
| Seqirus USA INC | $21.20 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Axsome Therapeutics, INC. | $20.94 | 2025 | Auvelity |
| Axonics, INC. | $17.04 | 2023 | Axonics |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.92 | 2024 | Xifaxan |
| Radius Health, INC. | $16.56 | 2021 | |
| Allergan, INC. | $16.00 | 2020 | |
| Novo Nordisk INC | $15.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.89 | 2025 | Airsupra |
| Gilead Sciences, INC. | $12.88 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.